United States: Updates On Patent Challenges By Biosimilar Manufacturers At The PTAB - Goodwin Procter LLP
Wednesday, 3 January 2024
In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents.
|
||||
You Might Like |
||||
